Multi-omics analysis reveals immune features associated with immunotherapy benefit in squamous cell lung cancer patients from Phase III Lung-MAP S1400I trial

CONCLUSIONS: The frequency, distribution and clustering of immune cells relative to malignant ones can impact ICI efficacy in SqNSCLC patients. High CNV burden may contribute to the cold immune microenvironment. Soluble inflammation/immune-related proteins in the blood have the potential to monitor therapeutic benefit from ICI treatment in SqNSCLC patients.PMID:38277235 | DOI:10.1158/1078-0432.CCR-23-0251

Source: Clinical Cancer Research - January 26, 2024 Category: Cancer & Oncology Authors: Edwin Roger Parra Jiexin Zhang Dzifa Yawa Duose Edgar Gonzalez-Kozlova Mary W Redman Hong Chen Ganiraju C Manyam Gayatri Kumar Jianhua Zhang Xingzhi Song Rossana Lazcano Mario L Marques-Piubelli Caddie Laberiano-Fernandez Frank Rojas Baili Zhang Len Taing Source Type: research